Quick Summary — BMRN scores higher on quality with 9.2/10 vs CADL's 4.4/10. BMRN trades at $53.32 while CADL trades at $8.42. Both analyzed daily using SEC EDGAR data across 13 institutional models.
BMRN scores higher with a 9.2/10 quality rating vs CADL's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
At $53.32, BMRN trades +46.5% above its Bayesian DCF fair value of $28.52, while CADL at $8.42 trades +59.6% above its estimate of $3.40. CADL shows a wider gap between price and intrinsic value.
BMRN earns a Quality of Company score of 9.2/10 compared to CADL's 4.4/10. This is a significant quality gap — the higher-scoring company demonstrates materially stronger fundamentals across profitability, growth consistency, and balance sheet health. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.
Review the value trap analysis for both BMRN and CADL to assess whether apparent undervaluation reflects genuine opportunity or hidden fundamental risk.
Both BMRN and CADL operate in Biotechnology, which has 566 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).
11 hidden models compare BMRN vs CADL differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.
Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day
See All 13 Models — $0.90/dayWe don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.